Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 14/20 | 0.40 |
| ▸ | ATRIP | Q8WXE1 | 9/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26297233 | 0.90 | RAD52 (0.45) | PIK3CDPIK3CAATRATRIPCHEK1 | |
| SCHEMBL30516414 | 0.87 | PIK3CD (0.46) | PIK3CDPIK3CAATRATRIPCHEK1 | |
| SCHEMBL25209606 | 0.85 | ATR (0.51) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL25407865 | 0.85 | ATR (0.51) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL26297256 | 0.80 | ATR (0.46) | PIK3CAATRATRIPCHEK1PDCD1 | |
| SCHEMBL25159980 | 0.79 | ATR (0.49) | PIK3CDPIK3CAATRATRIPCHEK1 | |
| SCHEMBL24961968 | 0.78 | MTOR (0.39) | PIK3CDPIK3CAATRATRIPCHEK1 | |
| SCHEMBL27233200 | 0.78 | MTOR (0.44) | PIK3CDPIK3CAATRATRIPCHEK1 | |
| SCHEMBL24961969 | 0.78 | MTOR (0.44) | PIK3CDPIK3CAATRATRIPCHEK1 | |
| SCHEMBL26297186 | 0.77 | ATR (0.51) | ATRATRIPCHEK1PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ATR, CHEK1, CHEK2 | PIK3CD 347/4885PIK3CA 317/4885ATR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.